Cited by 116Lipid metabolism and disordersLipid metabolism and biosynthesisLiver Disease Diagnosis and Treatment

Hepatocyte-specific suppression of ANGPTL4 improves obesity-associated diabetes and mitigates atherosclerosis in mice

Open access
Singh, Abhishek K., Chaube, Balkrishna, Zhang, Xinbo, Sun, Jonathan, Citrin, Kathryn M., Canfrán-Duque, Alberto, Aryal, Binod, Rotllan, Noemi, Varela, Luis, Lee, Richard G., Horvath, Tamas L., Price, Nathan L., Suárez, Yajaira, Fernández-Hernando, Carlos·2021·Journal of Clinical Investigation

Published version of a preprint

Abstract

Hepatic uptake and biosynthesis of fatty acids (FA), as well as the partitioning of FA into oxidative, storage, and secretory pathways are tightly regulated processes. Dysregulation of one or more of these processes can promote excess hepatic lipid accumulation, ultimately leading to systemic metabolic dysfunction. Angiopoietin-like-4 (ANGPTL4) is a secretory protein that inhibits lipoprotein lipase (LPL) and modulates triacylglycerol (TAG) homeostasis. To understand the role of ANGPTL4 in liver lipid metabolism under normal and high-fat fed conditions, we generated hepatocyte specific Angptl4 mutant mice (Hmut). Using metabolic turnover studies, we demonstrate that hepatic Angptl4 deficiency facilitates catabolism of TAG-rich lipoprotein (TRL) remnants in the liver via increased hepatic lipase (HL) activity, which results in a significant reduction in circulating TAG and cholesterol levels. Consequently, depletion of hepatocyte Angptl4 protects against diet-induce obesity, glucose intolerance, liver steatosis, and atherogenesis. Mechanistically, we demonstrate that loss of Angptl4 in hepatocytes promotes FA uptake which results in increased FA oxidation, ROS production, and AMPK activation. Finally, we demonstrate the utility of a targeted pharmacologic therapy that specifically inhibits Angptl4 gene expression in the liver and protects against diet-induced obesity, dyslipidemia, glucose intolerance, and liver damage, which likely occurs via increased HL activity. Notably, this novel inhibition strategy does not cause any of the deleterious effects previously observed with neutralizing antibodies.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci140989

Cites

76 of 76 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

2 of the 78 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Singh, A. K., Chaube, B., Zhang, X., Sun, J., Citrin, K. M., Canfrán-Duque, A., Aryal, B., Rotllan, N., Varela, L., Lee, R. G., Horvath, T. L., Price, N. L., Suárez, Y., & Fernández-Hernando, C.
Affiliations
  • Yale University (US)
  • Ionis Pharmaceuticals (United States) (US)
Corresponding author
Suárez, Yajaira
Venue
Journal of Clinical Investigation
Published
2021-09-01
Volume
131
Issue
17
ISSN
  • 0021-9738 (ISSN-L)
  • 1558-8238
OpenAlex
W3182800692
Cited by
115
References
78
Citations by year
2026: 12 · 2025: 29 · 2024: 28 · 2023: 16 · 2022: 17 · 2021: 12 · 2020: 1
FWCI
12.40
Type
journal article
Language
en
Open access
Locations
  • Journal of Clinical Investigation (publishedVersion)
  • bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Heart, Lung, and Blood Institute (R35HL135820)
  • National Institute of Diabetes and Digestive and Kidney Diseases (5F32DK10348902)
  • American Heart Association (16EIA27550005, 20TPA35490202, 17SDG33110002, 20TPA35490416)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Lipid metabolism and biosynthesis
  • Health Sciences › Medicine › Epidemiology › Liver Disease Diagnosis and Treatment
Keywords
ANGPTL4, hepatocyte-specific knockout, hepatic lipid metabolism, hepatic lipase, lipoprotein lipase, diet-induced obesity, impaired glucose tolerance, hepatic steatosis, atherosclerosis, fatty acid oxidation, AMPK activation, reactive oxygen species, dyslipidemia

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review